Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.34 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12513253 | 0.89 | BRD9 (0.35) | PDE4BBRPF1BRD9BRD7PDE3A | |
| SCHEMBL7950914 | 0.85 | BRPF1 (0.34) | PDE4BBRPF1BRD9 | |
| SCHEMBL2171854 | 0.81 | F11 (0.36) | PDE4BPDE3A | |
| SCHEMBL2171427 | 0.80 | PDE4B (0.52) | PDE4BPDE3A | |
| SCHEMBL2232652 | 0.79 | CYP11B1 (0.39) | PDE4BPDE3A | |
| SCHEMBL2232273 | 0.77 | PDE4B (0.41) | PDE4BPDE3A | |
| SCHEMBL2216271 | 0.76 | MEN1 (0.39) | PDE4BPDE3A | |
| SCHEMBL12436151 | 0.76 | HSD17B1 (0.42) | PDE4BPDE3A | |
| SCHEMBL2172407 | 0.76 | CYP11B1 (0.45) | PDE3A | |
| SCHEMBL12436146 | 0.75 | CYP1A2 (0.41) | PDE4BPDE3APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348018-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-07-27 | — | — | EP | claimed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | claimed |
| EP-2348018-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| WO-2010035745-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | 杏林製薬株式会社 (JP) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | PDE3A, PDE2A, PDE3B | PDE4B 6/4885BRPF1 818/4885BRD9 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.